Tomaralimab  (Synonyms: OPN-305)

Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury^{[1][2][3][4][5]}.

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Tomaralimab (100-500 nM; 20 h) dose-dependently inhibits oligomeric tau-induced TLR2 activation in HEK-Blue hTLR2 cells, reducing SEAP levels ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tomaralimab (30 mg/kg; i.v.; once a week; 8-15 weeks) reduces tau pathology and microglial activation in rTg4510 tau transgenic mice, improving cognitive performance^[1].
Tomaralimab (25 mg/kg; i.v.; every other day; until day 19) attenuates DNCB‑induced atopic dermatitis (AD)‑like skin lesions in BALB/c mice^[2].
Tomaralimab (10 mg/kg; i.p.; twice weekly) suppresses tumor growth and reduces PCNA-positive proliferating cells in NSG mice with human pancreatic ductal adenocarcinoma (PDAC) xenografts^[3].
Tomaralimab (1.56-12.5 mg/kg; i.v.; 15 min before reperfusion) dose-dependently reduces infarct size by up to 45% and preserves cardiac function in porcine myocardial ischemia/reperfusion models^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7097  [NCBI]

O60603

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.32 kDa

1449294-76-1

Liquid

Colorless to light yellow

[Tomaralimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human TLR2 Protein can bind Tomaralimab. The EC₅₀ for this effect is 649.63 ng/mL.

• [1]. Kim Y, et al. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain Behav Immun. 2024 Oct;121:291-302.  [Content Brief]

  [2]. Yeo H, et al. Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model. Biomed Rep. 2024 Dec 30;22(3):41.  [Content Brief]

  [3]. Lundy J, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene. 2021 Oct;40(41):6007-6022.  [Content Brief]

  [4]. GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.

  [5]. Arslan F, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.  [Content Brief]